KUALA LUMPUR: RHB Research has initiated coverage on Hovid with a Buy call and a fair value of 46 sen as it offered investors exposure to both the pharmaceutical and healthcare industries, with non-cyclical earnings and a global market reach.
It said on Monday Hovid's future revenue drivers include the "patent cliff' phenomenon, in-house drug development, and capacity expansion".
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
